Published in Blood Weekly, November 16th, 2006
"Despite increasing use of rFVIIa in non-haemophiliac patients, it is unclear when rFVIIa might be effective. A single centre review of consecutive non-haemophiliac patients receiving rFVIIa for the management of severe haemorrhage," wrote K.M. Bowles and colleagues, Addenbrookes Hospital.
"Treatments with rFVIIa were at a dose of 90 mcg kg-1 repeated at three hourly intervals at the clinicians' discretion. Eighteen patients received rFVIIa. Six patients survived to discharge and...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.